ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Lupus nephritis"

  • Abstract Number: 0324 • ACR Convergence 2024

    Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials

    Daniel Nunez1, Jenell Volkov1, Jason Stadanlick1, Zachary Vorndran1, Alexandra Ellis1, Mallorie Werner1, Justin Cicarelli1, Jazmean Williams1, Fatemeh Nezhad1, Thomas Furmanak2, Quynh Lam1, Rebecca Estremera1, Yvonne White1, Jonathan Hogan1, Claire Miller1, Tahseen Mozaffar3, Saira Sheikh4, David Chang1 and Samik Basu1, 1Cabaletta Bio, Philadelphia, PA, 2Cabaletta Bio - Philadelphia, PA, Philadelphia, PA, 3The University of California, Irvine, Orange, CA, 4University of North Carolina at Chapel Hill, Chapel Hill, NC

    Background/Purpose: CD19 targeting chimeric antigen receptor (CAR) T cells have demonstrated durable drug-free responses and remission in patients with idiopathic inflammatory myopathies (IIM) and systemic…
  • Abstract Number: 0660 • ACR Convergence 2024

    Hydroxychloroquine Users at Lower Risk of Kidney Function Decline in Lupus Nephritis

    Shivani Garg1, Brad Rovin2, Brad Astor1, Tripti Singh1, Lexie Kolton1, Callie Saric1, S. Sam Lim3 and Christie Bartels4, 1University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, 2The Ohio State University, Columbus, OH, 3Emory University, Atlanta, GA, 4University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone in treatment of systemic lupus erythematosus (SLE), yet its role in preventing kidney function decline in lupus nephritis (LN)…
  • Abstract Number: 1511 • ACR Convergence 2024

    Lupus Nephritis and Response to Treatment in Latin America

    Rosana Quintana1, Romina Nieto2, Diana Carolina Fernández Ávila3, Rosa Serrano Morales4, Guillermina Harvey5, Lucia Hernandez6, Karen Roberts7, Marina Scolnik8, Carmen Funes Soaje9, Paula Alba10, Veronica Saurit11, Mercedes Garcia12, Guillermo Berbotto13, VERONICA BELLOMIO14, Wilfredo Patiño Grageda15, Graciela Gómez16, Cecilia Pisoni17, Ana Malvar18, Vicente Juarez19, Nilzio A. Da Silva20, ODIRLEI MONTICIELO21, Henrique Ataide Mariz22, Francinne Machado Ribeiro23, Eduardo Borba24, Luciana Parente24, Edgard Torres25, Oscar Neira26, Loreto Massardo27, Gustavo Aroca Martínez28, Carlos A. Cañas Davila29, Gerardo Quintana López30, Carlos Enrique Toro-Gutierrez31, Mario Moreno32, Andres Zuñiga33, Miguel Angel Saavedra Salinas34, Margarita Portela Hernandez35, Hilda Fragoso-Loyo36, Luis H. Silveira Torre37, Ignacio García De La Torre38, Carlos Abud Mendoza39, Marcos Fonseca Hernández40, Jorge Esquivel-Valerio41, Isabel Acosta Colman42, Jhonatan Losanto43, Claudia Selene Mora Trujillo44, Katiuzka Zuñiga Corrales45, Roberto Muñoz Louis46, Martin Rebella47, Álvaro Danza48 Manuel Ugarte-Gil49, Graciela Alarcon50, Urbano Sbarigia51, Federico Zazzetti52, Ashley Orillion53, Guillermo Pons-Estel54 and Bernardo Pons-Estel54, 1Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 2Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, 3Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, 4Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, 5Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina, Rosario, Argentina, 6Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, 7Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 8Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 9Hospital Italiano, Cordoba, Argentina, 10Hospital Cordoba, Cordoba, Spain, 11hospital privado universitario de cordoba, Córdoba, Argentina, 12HIGA San Martin, La Plata, Argentina, 13Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, ROSARIO, Argentina, 14Hospital Padilla, San Miguel de Tucumán, Argentina, 15Hospital General de Agudos Dr Ramos Mejia, CABA, Argentina, 16Instituto de Investigaciones Médicas Alfredo Lanari, Autónoma de Buenos Aires, Argentina, 17CEMIC, Buenos Aires, Argentina, 18Organización Médica de Investigación, Buenos Aires, Argentina, 19Hospital Señor del Milagro, Salta, Salta, Argentina, 20Hospital das Clinicas, Universidad Federal de Goias, Goias, Goias, Brazil, 21HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, 22Universidad Federal de Pernambuco, Pernambuco, Brazil, 23Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, 24Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 25Universidad Federal São Paulo, São Paulo, SP, Brazil, 26Hospital del Salvador, Santiago de Chile, Chile, 27Facultad de Medicina y Ciencia, Universidad San Sebastián, San Sebastián, Chile, 28Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, 29Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, 30Universidad de Los Andes, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia, 31Reference Center for Osteoporosis & Rheumatology, Cali, Colombia, 32Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, Guayaquil, Ecuador, 33Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, 34División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, 35Departamento de Reumatología del Hospital de especialidades del Centro Médico Nacional Siglo XXI del Instituto Mexicano del Seguro Social (IMSS), Mexico, Mexico, 36Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, 37Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, 38Depto. de Inmunología y Reumatología; Centro de Estudios de Investigación Básica y Clínica, Guadalajara, Mexico, 39Hospital Central Dr. Ignacio Morones Prieto, SLP, México, SLP, Mexico, 40Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, Mexico, 41Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, 42Hospital de Clínicas I, Asunción, Paraguay, 43Hospital de Clínicas I, San Lorenzo, Paraguay, 44Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, 45Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, 46Hospital Docente Padre Billini, Santo Domingo, República Dominicana, Santo Domingo, Dominican Republic, 47Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, 48Médica Uruguaya Corporación de Asistencia Médica (MUCAM). Clínica Médica - Facultad de Medicina - UdelaR, Montevideo, Uruguay, 49Universidad Cientifica del Sur, Lima, Lima, Peru, 50The University of Alabama at Birmingham, Birmingham, AL, 51Johnson & Johnson Innovative Medicine, Brussels, Belgium, 52Johnson & Johnson Innovative Medicine, Horsham, PA, PA, 53Johnson & Johnson Innovative Medicine, Spring House, PA, PA, 54Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina

    Background/Purpose: The Latin American Group for the Study of Lupus (GLADEL) 2.0 is an observational prevalent and incident cohort of patients with systemic lupus erythematosus…
  • Abstract Number: 1803 • ACR Convergence 2024

    Genetics of eGFR Variability as a Proxy for Lupus Nephritis in Patients with Systemic Lupus Erythematosus

    Magdalena Riedl Khursigara1, Nicholas Gold2, Thai-Son Tang3, JingJing Cao4, Daniela Dominguez4, Marisa Klein-Gitelman5, Dafna Gladman6, Daniel Goldman7, Elizabeth Harvey4, Mariko Ishimori8, Caroline Jefferies9, Diane Kamen10, Sylvia Kamphuis11, Andrea Knight12, Chia-Chi Lee13, Deborah Levy2, Damien Noone4, Karen Onel14, Christine Peschken15, Michelle Petri7, Janet Pope16, Eleanor Pullenayegum4, Earl Silverman17, Zahi Touma18, Murray Urowitz19, Daniel Wallace20, Joan Wither21 and Linda Hiraki2, and Systemic Lupus Erythematosus Collaborative Clinics (SLICC), 1University of Toronto, Cambridge, MA, 2The Hospital for Sick Children, Toronto, ON, Canada, 3University of Toronto, Mississauga, ON, Canada, 4The Hospital for Sick Children, Toronto, Canada, 5Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 6University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 7Johns Hopkins University School of Medicine, Timonium, MD, 8Cedars-Sinai Health System, Los Angeles, CA, 9Cedars-Sinai Medical Center, Beverly Hills, CA, 10Medical University of South Carolina, Charleston, SC, 11Erasmus University Medical Center, Rotterdam, Netherlands, 12Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 13Cedars-Sinai Medical Center, Los Angeles, CA, 14HSS, New York, NY, 15University of Manitoba, Winnipeg, MB, Canada, 16University of Western Ontario, London, ON, Canada, 17Silverman, Toronto, ON, Canada, 18University of Toronto, Toronto, ON, Canada, 19Self employed, Toronto, ON, Canada, 20Cedars Sinai Medical Center, Studio City, CA, 21University Health Network, Toronto, ON, Canada

    Background/Purpose: Lupus nephritis (LN) is one of the most common and severe manifestations of systemic lupus erythematosus (SLE). We performed genome wide association studies (GWAS)…
  • Abstract Number: 2395 • ACR Convergence 2024

    Validation Cohort of a Tool to Predict Proliferative Histological Class in Lupus Nephritis Based on Clinical and Laboratory Data – LUCAS Study (Lupus Nephritis Class Assessment System)

    Antônio Silaide De Araújo-Júnior1, Emília Sato2, Alexandre Wagner Silva de Souza1, Fábio Jennings1, Gianna Mastroianni Kirsztajn3, Ricardo Sesso3 and Edgard Reis Neto4, 1Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil., São Paulo, SP, Brazil, 2Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, 3Division of Nephrology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil., São Paulo, SP, Brazil, 4Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal, São Paulo, SP, Brazil

    Background/Purpose: Lupus nephritis (LN) is an important cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE), and kidney biopsy is the gold…
  • Abstract Number: 0445 • ACR Convergence 2024

    Evaluating Clinical Reasoning in Randomized Surveys of Lupus Nephritis and Preeclampsia Pregnancy Case Workups: A Clinical Conundrum

    Liya Stolyar1, Sadaf Sediqi2, Richard Lafayette3, Maurice Druzin4, Saadiya Hawa5, Amanda Moyer6, Yashaar Chaichian2 and Julia Simard2, 1Palo Alto VA Medical Center/Stanford, Stanford, CA, 2Stanford School of Medicine, Stanford, CA, 3Stanford, Stanford, CA, 4Stanford University School of Medicine, Stanford, CA, 5Weiss Memorial Hospital, Chicago, IL, 6Stanford University, San Bruno, CA

    Background/Purpose: Systemic lupus erythematosus (SLE) pregnancy is associated with a heightened risk of adverse pregnancy outcomes, including preeclampsia. Distinguishing preeclampsia from lupus nephritis (LN) presents…
  • Abstract Number: 0661 • ACR Convergence 2024

    Validity, Reliability and Responsiveness of Lupus Impact Tracker and LupusPRO: AURORA Trial

    Meenakshi Jolly1, Matt Truman2, Ronald Flauto3 and Kathryn Dao4, and AURORA, 1Rush University Medical Center, Chicago, 2Aurinia Pharmaceuticals, Victoria, BC, Canada, 3Aurinia Pharmaceuticals, Rockville, MD, 4Aurinia Pharmaceuticals, Dallas

    Background/Purpose: Voclosporin used in addition to Mycophenolate Mofetil and low dose oral steroids in patients with active Lupus Nephritis (LN) was found to be superior…
  • Abstract Number: 1518 • ACR Convergence 2024

    Predictive Value of Chronic Histologic Changes in Lupus Nephritis

    Maria Cuellar-Gutierrez1, Jaime Flores Gouyonnet1, Gabriel Figueroa-Parra2, Marta Casal Moura1, Fernando C. Fervenza1, Andrew C. Hanson3, Cynthia Crowson1, Sanjeev Sethi1 and Ali Duarte-Garcia1, 1Mayo Clinic, Rochester, MN, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 3Mayo Clinic, Rochester

    Background/Purpose: We aimed to assess the predictive value of the individual components of the NIH chronicity score and the Mayo Clinic Chronicity Score (MCCS) in…
  • Abstract Number: 1808 • ACR Convergence 2024

    Not Only Type-I Interferon Regulated Genes Are Differentially Expressed in Circulating Monocytes from Active Lupus Nephritis Patients

    Paula Losada Vanegas1, Juan Antonio Villatoro-García2, Daniel Rodriguez3, Juan Camilo Diaz3, Ricardo Pineda4, Pedro Carmona-Saez5, Mauricio Rojas6 and Gloria Vasquez7, 1Universidad de Antioquia, Medellin, Antioquia, Colombia, 2GENYO (Centre for Genomics and Oncological Research: Pfizer, University of Granada, Granada, Andalucia, Spain, 3ARTMEDICA, Medellín, Antioquia, Colombia, 4ARTMEDICA, Medellin, Antioquia, Colombia, 5GENYO (Centre for Genomics and Oncological Research: Pfizer, University of Granada, Granada, Asturias, Spain, 6Grupo de Inmunología Celular e Inmunogenética, Sede de Investigación Universitaria. Facultad de Medicina. Universidad de Antioquia, Medellin, Antioquia, Colombia, 7Grupo de Inmunología Celular e Inmunogenética, Sede de Investigación Universitaria. Facultad de Medicina.Universidad de Antioquia, Medellin, Colombia

    Background/Purpose: Monocytes play an important role in organ damage, such as in Lupus Nephritis (LN). Although monocytes are typically considered inflammatory cells, evidence shows they…
  • Abstract Number: 2411 • ACR Convergence 2024

    Attainment of Complete Renal Response in Patients with Active Lupus Nephritis: A Multi-Center Cohort Study

    Arushi Ramnarain1, Xiaomeng Xu2, Joanna Kent3, Sagar Jagtiani4, Worawit Louthrenoo5, Laniyati Hamijoyo6, Shue-Fen Luo7, Yi-Hsing Chen8, Jiacai Cho9, Chiu Wai Shirley Chan10, Sandra Navarra11, Haihong Yao12, Lydia Pok13, BMDB Basnayake14, Zhuoli Zhang15, Madelynn Chan16, Sang-Cheol Bae17, Yasuhiro Katsumata18, Jun Kikuchi19, Sean O'Neill20, Fiona Goldblatt21, Yih Jia Poh22, Mark Sapsford23, Nicola Tugnet24, Kristine Pek Ling Ng25, Cherica Tee26, Yoshiya Tanaka27, Mandana Nikpour28, Alberta Hoi29, Eric Morand30 and Rangi Kandane-Rathnayake31, 1Monash Health, Melbourne, Victoria, Australia, 2GSK, Value, Evidence & Outcomes, Singapore, Singapore, 3Monash University, Department of Nephrology, Monash Health and Department of Medicine, Melbourne, Australia, 4Glaxo Smith Kline, Singapore, Singapore, 5Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Chiang Mai, Thailand, 6Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, 7Chang Gung Memorial Hospital, Taipei, Taiwan, 8Taichung Veterans General Hospital, Taichung, TW, Taichung, Taiwan (Republic of China), 9National University Hospital, Singapore, Singapore, 10Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, 11University of Santo Tomas, Manila, Philippines, 12People's Hospital, Peking University Health Science Center, Department of Rheumatology and Immunology, Beijing, China, 13University of Malaya Medical Center, Department of Medicine, Faculty of Medicine,, Kuala Lumpur, Malaysia, 14Teaching Hospital, Kandy, Sri Lanka, 15Peking University First Hospital, Beijing, China, 16Tan Tock Seng Hospital, Singapore, Singapore, 17Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 18Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 19Keio University School of Medicine, Tokyo, Japan, 20Liverpool Hospital; Royal North Shore Hospital; University of New South Wales and the University of Sydney, Sydney, New South Wales, Australia, 21Flinders Medical Centre, Adelaide, Australia, 22SingHealth, Singapore, Singapore, 23WDHB, Auckland, New Zealand, 24Auckland District Health Board, Auckland, New Zealand, 25Health New Zealand, Auckland, New Zealand, 26Department of Pediatrics, College of Medicine, University of the Philippines, Manila, Philippines, 27Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 28The University of Sydney, Melbourne, Victoria, Australia, 29Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, 30School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, 31Monash University, Clayton, Victoria, Australia

    Background/Purpose: LN is prevalent in SLE, occurring in up to 50% of patients. Treatment response is evaluated by improvement in proteinuria and renal function, and…
  • Abstract Number: 0607 • ACR Convergence 2024

    Plasma Proteomic Analysis Reveals Type I Interferon Blockade Effects of Anifrolumab in Lupus Nephritis: Insights from a Phase 2 Trial

    Andrea Fava1, Michelle Petri2, David Jayne3, Patrick G Gavin4, Eszter Csomor5, Philip Z Brohawn4, Daniel Muthas6, Adam Platt5, Catharina Lindholm7 and Nicola Ferrari5, 1Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University School of Medicine, Timonium, MD, 3University of Cambridge, Cambridge, United Kingdom, 4BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 5BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 6BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 7BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden

    Background/Purpose: An elevated type I interferon gene signature (IFNGS) is associated with more active disease in patients with LN.1 Anifrolumab, a type I interferon receptor…
  • Abstract Number: 0663 • ACR Convergence 2024

    Treatment Patterns and the Prevalence of Kidney Biopsy-Confirmed LN in Patients with SLE and Proteinuria: A Multicenter Cohort Study

    Arushi Ramnarain1, Xiaomeng Xu2, Joanna Kent3, Sagar Jagtiani4, Worawit Louthrenoo5, Laniyati Hamijoyo6, Shue-Fen Luo7, Yi-Hsing Chen8, Jiacai Cho9, Chiu Wai Shirley Chan10, Sandra Navarra11, Haihong Yao12, Lydia Pok13, BMDB Basnayake14, Zhuoli Zhang15, Madelynn Chan16, Sang-Cheol Bae17, Yasuhiro Katsumata18, Jun Kikuchi19, Sean O'Neill20, Fiona Goldblatt21, Yih Jia Poh22, Mark Sapsford23, Nicola Tugnet24, Kristine Pek Ling Ng25, Cherica Tee26, Yoshiya Tanaka27, Mandana Nikpour28, Alberta Hoi29, Eric Morand30 and Rangi Kandane-Rathnayake31, 1Monash Health, Melbourne, Victoria, Australia, 2GSK, Value, Evidence & Outcomes, Singapore, Singapore, 3Monash University, Department of Nephrology, Monash Health and Department of Medicine, Melbourne, Australia, 4Glaxo Smith Kline, Singapore, Singapore, 5Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Chiang Mai, Thailand, 6Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, 7Chang Gung Memorial Hospital, Taipei, Taiwan, 8Taichung Veterans General Hospital, Taichung, TW, Taichung, Taiwan (Republic of China), 9National University Hospital, Singapore, Singapore, 10Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, 11University of Santo Tomas, Manila, Philippines, 12People's Hospital, Peking University Health Science Center, Department of Rheumatology and Immunology, Beijing, China, 13University of Malaya Medical Center, Department of Medicine, Faculty of Medicine,, Kuala Lumpur, Malaysia, 14Teaching Hospital, Kandy, Sri Lanka, 15Peking University First Hospital, Beijing, China, 16Tan Tock Seng Hospital, Singapore, Singapore, 17Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 18Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 19Keio University School of Medicine, Tokyo, Japan, 20Liverpool Hospital; Royal North Shore Hospital; University of New South Wales and the University of Sydney, Sydney, New South Wales, Australia, 21Flinders Medical Centre, Adelaide, Australia, 22SingHealth, Singapore, Singapore, 23WDHB, Auckland, New Zealand, 24Auckland District Health Board, Auckland, New Zealand, 25Health New Zealand, Auckland, New Zealand, 26Department of Pediatrics, College of Medicine, University of the Philippines, Manila, Philippines, 27Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 28The University of Sydney, Melbourne, Victoria, Australia, 29Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, 30School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, 31Monash University, Clayton, Victoria, Australia

    Background/Purpose: LN is a common and severe manifestation of SLE. Although proteinuria is a useful diagnostic indicator, kidney biopsy is necessary for definitive diagnosis and…
  • Abstract Number: 1521 • ACR Convergence 2024

    Contemporary Lupus Nephritis Treatment and Outcomes Among Patients with Systemic Lupus Erythematosus in the United States

    Aakash Patel1, Baijun Zhou2, Hyon K. Choi3 and April Jorge1, 1Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Lupus nephritis (LN) is associated with excess morbidity and mortality, with prior studies finding a disproportionate impact on Black patients. We sought to determine…
  • Abstract Number: 1811 • ACR Convergence 2024

    The Immune Map of Lupus Nephritis: A Spatially Resolved Kidney Proteomic Approach

    Chen-Yu Lee1, Matthew Caleb Marlin2, Xiaoping Yang1, Alessandra Ida Celia3, Vasileios Morkotinis4, Richard Furie5, Jill Buyon6, Chaim Putterman7, Jennifer Barnas8, Kenneth Kalunian9, Peter Izmirly10, Betty Diamond11, Anne Davidson12, Diane Kamen13, Jeff Hodgin14, the Accelerating Medicines Partnership RA/SLE15, Judith James2, Michelle Petri16, Joel Guthridge2, Avi Rosenberg1 and Andrea Fava1, 1Johns Hopkins UNiversity, Baltimore, MD, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Sapienza University of Rome, Rome, Italy, 4University of Oklahoma Health Sciences Center, Oklahoma City, OK, 5Northwell Health, Manhasset, NY, 6NYU Grossman School of Medicine, New York, NY, 7Albert Einstein College of Medicine, Safed, Israel, 8University of Rochester, Rochester, NY, 9University of California San Diego, La Jolla, CA, 10New York University Grossman School of Medicine, New York, NY, 11The Feinstein Institutes for Medical Research, Manhasset, NY, 12Feinstein Institutes for Medical Research, Manhasset, NY, 13Medical University of South Carolina, Charleston, SC, 14University of Michigan, Michigan, 15multiple, multiple, 16Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Treatment response rates in lupus nephritis (LN) remain suboptimal, highlighting the need for a better understanding of LN pathogenesis to enhance treatment strategies. Single-cell…
  • Abstract Number: 2415 • ACR Convergence 2024

    Characterizing the Population with Suspected Lupus Nephritis in Care of a Community Rheumatology Network

    Nehad Soloman1, Jawad Bilal2, Romy Cabacungan3, Scott Milligan4, Andrew Sharobeem5, John Tesser6 and Henry Leher7, 1Arizona Arthritis & Rheumatology Associates, P.C., Glendale, AZ, 2University of Arizona, Tucson, AZ, 3Arizona Arthritis & Rheumatology Associates, P.C., Tucson, AZ, 4Trio Health, Louisville, CO, 5AARA, Peoria, AZ, 6Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 7Aurinia Pharma, Stowe, VT

    Background/Purpose: Lupus nephritis (LN) has been estimated to develop in up to 40% of all patients with systemic lupus erythematosus (SLE), with higher rates in…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 37
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology